CreatiPhage Biotech

CreatiPhage is a synthetic biology-driven biotechnology company specializing in the development of engineered bacteriophage therapies to combat multidrug-resistant bacterial infections. The company leverages a proprietary platform to design and optimize synthetic phages with enhanced host range, stability, and bactericidal activity. Their pipeline targets high-priority pathogens such as Klebsiella pneumoniae and Pseudomonas aeruginosa, addressing critical unmet needs in infectious disease management. CreatiPhage aims to provide precision antimicrobial solutions as an alternative or adjunct to traditional antibiotics. The company has successfully demonstrated clinical proof-of-concept through investigator-initiated trials for severe drug-resistant infections. By utilizing high-throughput screening and modular genetic engineering, the firm is working toward standardized, off-the-shelf phage products.